Research Interests
Development of a Novel Family of Antitumor
Agents Targeting Cdc2 Kinase and Survivin
Our laboratory has extensively investigated the use of derivatives
of the plant lignan nordihydroguaiaretic acid (NDGA) for blocking
viral replication through the inhibition of viral transcription.
We have shown that NDGA derivatives, originally isolated from
the creosote bush, Larrea tridentata, and now synthesized
chemically, can inhibit the production of HIV, HSV and HPV transcripts
by the deactivation of their Sp1-dependent promoters. An unexpectant
outgrowth of this research has been the finding that one of
the derivatives, tetra-O-methyl NDGA (M4N),
also induces cell cycle arrest in mammalian tumor cell lines.
When treated with M4N, tumor cells in culture arrest
in the G2 phase of the cell cycle. Arrest appears
to be the direct result of inhibition of transcription of the
cdc2 gene, whose expression is dependent on Sp1 and whose gene
product is a cyclin kinase required for formation of the Maturation
Promoting Factor complex. The discovery of the antiproliferative
activity of M4N led us to investigate whether it
could be an effective antitumor agent. Injection of the water
insoluble M4N compound into experimentally induced
mouse tumors resulted in arrest of tumor growth with minimal
toxicity to the surrounding normal tissues. Our most recent
work suggests that M4N induces apoptosis in these
tumors as well. Several mouse tumor models are being used
to test new water-soluble NDGA derivatives that we hope can
be used systemically to treat metastatic disease.
Inhibition of Herpes Simplex Virus Infection by Nordihydroguaiaretic
Acid Plant Lignan Derivatives
Herpes simplex virus type 1 (HSV-1) is a DNA virus afflicting
greater than 70% of the human population. During an HSV-1
lytic infection, viral genes are expressed in a tightly regulated
cascade. In this cascade, several of the HSV-1 genes are
dependent on the Sp1 protein for their expression, and may serve
as targets for viral inhibition. The immediate early ICP4
gene is an attractive target as it is among the first genes
to be expressed in the lytic cascade, and its expression is
absolutely essential for the expression of subsequent viral
genes and HSV-1 replication. Our lab has demonstrated
that NDGA plant lignan derivatives inhibit replication of HSV-1
in infected Vero cells and prevent the binding of Sp1 to cognate
sites on the HSV-1 ICP4 promoter. We are interested in
developing these compounds as effective treatment modalities
for herpes labialis and genital herpes. Studies using
newly synthesized water-soluble derivatives of NDGA in mouse
models of HSV infection are underway.
A Series of Antiviral Agents Derived from Natural Products
for Use in Combination Therapy of HIV-1
The AIDS epidemic continues to be a devastating
problem for millions of people in the world. Our success with
M4N and other NDGA derivatives as effective inhibitors
of HIV replication has encouraged us to pursue an anti-HIV therapeutic
approach that involves a cocktail of three compounds that inhibit
different steps in the HIV life cycle. In addition to the NDGA
derived transcription inhibitors, our lab has also isolated
two saponins from the African rain forest tree Tieghemela
heckelii that inhibit viral entry. Tieghemelin and arganine
C are potent inhibitors of HIV mediated cell-cell fusion and
inhibit HIV replication in infected cells in culture.
We have also targeted viral integration and have purified two
potent inhibitors of HIV integrase, lithospermic acid and lithospermic
acid B, from the roots of Salvia miltiorrhiza.
They are also potent inhibitors of HIV replication. All
of the NDGA compounds targeting transcription factors have been
found to be mutation insensitive and should therefore increase
the effectiveness and reduce the toxicity of the therapy. We
are currently testing these three classes of compounds in combination
for their effectiveness at blocking HIV production in cell culture.
As a therapeutic regimen is developed, the lab will be intensely
involved in studying the molecular mechanisms by which these
compounds exert their pharmacological activity.
A Self-Inducing Runaway-Replication Plasmid Protein Expression
System
A
unique, highly efficient prokaryotic expression system has been
developed in our laboratory that produces unparalleled amounts
of protein. The system consists of a temperature-sensitive-copy-number
plasmid that carries the rop gene and promoter downstream from
the trp promoter. Any sequence cloned into the rop gene alters
Rop protein activity and causes lethal runaway plasmid DNA replication.
This plasmid replication can be suppressed in trans by complementation
with a similar wild-type plasmid. Cells harboring both plasmids
are quite stable, and induction of plasmid DNA synthesis occurs
only after cells are grown for several generations under conditions
that lead to the loss of the trans-acting repressor. Large amounts
of Rop fusion proteins accumulate in the cell as the trp operon
is gradually induced via repressor titration. The success of
the Human Genome Project has opened the door to a myriad of
new proteins and potential therapeutic entities. We are continuing
to refine this protein expression system so that it can be a
universally effective tool for investigators in the burgeoning
field of proteomics.
Regulation of Zebrafish Egg Envelope Gene Expression
The discovery by our laboratory of a winter flounder ZPB gene
homologue first established that the major proteins of fish
egg envelopes are closely related to those of the mammalian
zona pellucida. We are currently using the zebrafish egg envelope
as a starting point for comparative studies aimed at understanding
mammalian folliculogenesis and oocyte formation. A cluster of
genes coding for the major egg envelope protein of zebrafish
has been isolated and analysis of the nucleotide sequence upstream
of the genes has revealed the presence of E-box elements similar
to those found in mouse and human zona pellucida gene promoters
that are known to be essential for coordinated oocyte-specific
gene expression. In the mouse, a germ cell specific transcription
factor, FIGa, has been shown to bind to the E-box and play a
key role in regulating the expression of zona pellucida genes
as well as other oocyte-specific genes, including those that
initiate folliculogenesis. We are interest in finding the factors
that are responsible for regulating these processes in the zebrafish
and the mechanisms by which they effect chromatin structure
and function.
Representative
Publications
Yeh, H-C., Puleo, C., Lim, T.C., Ho, Y-P., Giza, P., Huang, R.C.C., Wang, T-H. 2006. A microfluidic-FCS platform for investigation on the dissociation of Sp1-DNA complex by doxorubicin. Nuc Acids Res, Accepted for publication.
Chang, C.C., Liang, Y.C., Klutz, A., Hsu, C.I., Lin, C.F., Mold, D.E., Chou, T.C., Lee, Y.C., Huang R.C.C. 2006. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and Maltose- M3N, and their use in combination with Doxorubicin or Paclitaxel. Cancer Chemother Pharmacol. 58:640-653.
Huang, R.C.C., Chang, C-C., and Mold, D.E. 2006. Survivin Dependent and Independent Pathways and the Induction of Cancer Cell Death by Tetra-O-methyl Nordihydroguaiaretic Acid. Eds. Daniel Van Hoff and Philip J. Gray, Jr. Invited Article, Seminars in Oncology 33:479-485.
Dohm, J.A., Hsu, M-H., Hwu, J-R., Huang ,R.C.C., Moudrianakis, E.N., Lattman, E.E., Gittis, A.G. 2005. Influence of polyamines, ions, hydration, and the transcriptional inhibitor P4N on the conformations of the Sp1 binding site. J. Molec. Bio. 349:731-744.
Park, R., Chang, C-C., Liang, Y-C., Chung, Y., Henry, R.A., Lin, E., Mold, D.E., Huang, R.C.C. 2005. Systemic treatment with tetra-o-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. Clinical Cancer Res. 11:4601-4609.
Hansel, D.E., Dhara, S., Huang, R.C.C., Ashfaq, R., Deasel, M., Shimada, Y., Bernstein, H.S., Harmon, J., Brock, M., Forastiere, A., Washington, M.K., Maitra, A., Montgomery, E. 2005. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol. 29:390-399.
Chang, C-C., Heller, J.D., Kuo, J., Huang, R.C.C.2004. Tetra-O-methyl
nordihydroguaiaretic acid induces growth arrest and cellular apoptosis
of C3 transformed cells by suppressing cdc2 and survivin
expression. Proc Natl Acad Sci USA. 101:13239-13244.
Gosse, B.K., Ito, Y., Huang, R.C.C. 2004. Optimization of active saponin,
arganine C, for microbicidal external use. J Liq Chromatogr Rel
Technol. 27:1947-1953.
Huang, R.C.C, Li, Y., Giza, P.E., Gnabre, J.N., Abd-Elazem, I.S., King, K.Y., Hwu, J.R. 2003.
Novel antiviral agent tetraglycylated nordihydroguaiaretic acid
hydrochloride as a host-dependent viral inhibitor. Antiviral Res. 58:57-64.
Park, R., Giza, P.E., Mold, D.E., Huang, R.C.C. 2003 Inhibition of HSV-1
replication and reactivation by the mutation-insensitive transcription
inhibitor tetra-O-glycyl-nordihydroguaiaretic acid. Antiviral Res. 58:35-45.
Gosse, B.K., Gnabre, J.N., Bates, R.B., Nakkiew, P., Huang, R.C.C. 2002. Antiviral
saponins from Tieghemella heckelii. J Nat Products. 65:1942-1944.
Gosse, B.K., Gnabre, J.N., Ito, Y., Huang, R.C. 2002 Isolation of saponins
with viral entry inhibitory activity by combined chromatographic
methods. J Liq Chromatogr Rel Technol. 25:3197-3209.
Abd-Elazem, I.S., Chen, H.S., Bates, R.B., Huang, R.C.C. 2002 Isolation of two
highly potent and non-toxic inhibitors of human immunodeficiency virus
type 1 (HIV-1) integrase from Salvia miltiorrhiza. Antiviral Res. 55:91-106.
Heller, J.D., Kuo, J., Wu, T.C., Kast, W.M., Huang, R.C.C. 2001 Tetra-O-methyl
nordihydroguaiaretic acid induces G2 arrest in mammalian
cells. Cancer Res. 61:5499-5504.
Mold, D.E., Kim, I.F., Tsai, C-M., Lee, D., Chang, C-Y., Huang, R.C.C. 2001 Cluster
of genes encoding the major egg envelope protein of zebrafish. Mol
Reprod Dev. 58:4-14.
Craigo, J., Callahan, M., Huang, R.C., Delucia, A.L. 2000. Inhibition of human
papilloma virus type 16 gene expression by nordihydroguaiaretic acid
plant lignan derivatives. Antiviral Res. 47:19-28.
|